Phenotypic features of children with neurodevelopmental diseases in relation to biogenic amines

Respiratory Physiology and Neurobiology

Volumn 209, Issue , 2015, Pages 124-132

  Szymańska, Krystyna ^a,b   Kuśmierska, Katarzyna ^c   Nowacka, Maria ^c   Sykut Cegielska, Jolanta ^c   Demkow, Urszula ^b  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

Biogenic amines; Children; Dopamine; Neurodevelopmental syndrome; Phenotype; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BIOGENIC AMINE; DOPAMINE; SEROTONIN;

ARTICLE; ATAXIA; CEREBROSPINAL FLUID; CHILD; CHOREA; DYSTONIA; EPILEPSY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; HYPERKINESIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PYRAMIDAL SIGN; RIGIDITY; TREMOR; ADOLESCENT; ADULT; DISEASE COURSE; FOLLOW UP; INFANT; MULTIVARIATE ANALYSIS; NEURODEVELOPMENTAL DISORDERS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; BIOGENIC AMINES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEURODEVELOPMENTAL DISORDERS; PHENOTYPE; YOUNG ADULT;

EID: 84928347580     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2014.12.007     Document Type: Article

References (53)

1. Ashwal S., Russman B.S., Blasco P.A., Miller G., Sandler A., Shevell M., Stevenson R. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004, 62:851-863.
2. Bagdy G., Kecskemeti V., Riba P., Jakus R. Serotonin and epilepsy. J. Neurochem. 2007, 100:857-873.
3. Barnes J.J., Dean A.J., Nandam L.S., O'Connell R.G., Bellgrove M.A. The molecular genetics of executive function: role of monoamine system genes. Biol. Psychiatry 2011, 69:e127-e143.
4. Blau N., Thony B., Cotton R., Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. The Metabolic and Molecular Basis of Inherited Disease 2001, 1725-1776. McGraw Hill, New York. C. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
5. Blau N., Hennermann J.B., Langenbeck U., Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol. Genet. Metab. 2011, 104:S2-S9. 10.1016/j.ymgme. 08.017.
6. Bozzi Y., Borrelli E. The role of dopamine signalling in epileptogenesis. Front. Cell. Neurosci. 2013, 10.3389/fncel.2013.00157.
7. Chongsuvivatwong V, 2012. Epicalc: epidemiological calculator. R package version 2.15.1.0. http://CRAN.R-project.org/package=epicalc.
8. Devinsky O., Emoto S., Goldstein D.S. CSF and serum levels of DOPA, catechols, and monoamine metabolites in patients with epilepsy. Epilepsia 1992, 33:263-270.
9. Duarte S., Sanmartí F., González V., Perez- Dueñas B., Ormazabal A., Artuch R., Campistol J., Garcia-Cazorla A. Cerebrospinal fluid pterins and neurotransmitters in early severe epileptic encephalopathies. Brain Dev. 2008, 30:106-111.
10. Echenne B., Roubertie A., Leydet J., Rivier F., Hoffmann G.F. Monoamine metabolism study in severe, early-onset epilepsy in childhood. Epileptic Disord. 2008, 10:130-135.
11. Esposito E., Di Matteo V., Di Giovanni G. Serotonin-dopamine interaction: an overview. Prog. Brain Res. 2008, 172:3-6. 10.1016/S0079-6123(08)00901-1.
12. Friedman J., Roze E., Abdenur J.E., Chang R., Gasperini S., Saletti V., Wali G.M., Eiroa H., Neville B., Felice A., Parascandalo R., Zafeiriou D.I., Arrabal-Fernandez L., Dill P., Eichler F.S., Echenne B., Gutierrez-Solana L.G., Hoffmann G.F., Hyland K., Kusmierska K., Tijssen M.A., Lutz T., Mazzuca M., Penzien J., Poll-The B.T., Sykut-Cegielska J., Szymanska K., Thöny B., Blau N. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012, 71:520-530. 10.1002/ana.22685.
13. Garcia J.A.B. Activity of the behavioural activation system and the behavioural inhibition system and psychopathology. J. Clin. Health Psychol. 2010, 6:57-60.
14. García-Cazorla A., Serrano M., Pérez-Dueñas B., González V., Ormazábal A., Pineda M., Fernández-Alvarez E., Campistol J., Artuch R. Secondary abnormalities of neurotransmitters in infants with neurological disorders. Dev. Med. Child Neurol. 2007, 49:740-744.
15. García-Cazorla A., Duarte S., Serrano M., Nascimento A., Ormazábal A., Carrilho I., Briones P., Montoya J., Garesse R., Sala-Castellvi P., Pineda M., Artuch R. Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 2008, 8:273-278.
16. García-Cazorla A., Wolf N.I., Serrano M., Pérez-Dueñas B., Pineda M., Campistol J., Fernández-Alvarez E., Colomer J., DiMauro S., Hoffmann G.F. Inborn errors of metabolism and motor disturbances in children. J. Inherit. Metab. Dis. 2009, 32:618-629.
17. García-Cazorla A., Duarte S.T. Parkinsonism and inborn errors of metabolism. J Inherit. Metab. Dis. 2014, 10.1007/s10545-014-9723-6.
18. De Grandis E., Serrano M., Pérez-Dueñas B., Ormazábal A., Montero R., Veneselli E., Pineda M., González V., Sanmartí F., Fons C., Sans A., Cormand B., Puelles L., Alonso A., Campistol J., Artuch R., García-Cazorla A. Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J. Inherit. Metab. Dis. 2010, 33:803-809. 10.1007/s10545-010-9200-9.
19. Gray J.A., McNaughton N. The Neuropsychology of Anxiety: An Enquiry into the Functions of the Septo-Hippocampal System 2000, Oxford University Press, Oxford.
20. Hammer Ø., Harper D.A.T., Ryan P.D. Past: paleontological statistics software package for education and data analysis. Palaeontol. Electron. 2001, 4:9.
21. Hanley G.E., Brain U., Oberlander T.F. Infant developmental outcomes following prenatal exposure to antidepressants and maternal depressed mood and positive affect. Early Hum. Dev. 2013, 89:519-524.
22. Heales S.J.R. Biogenic amines. Laboratory Guide to the Methods in Biochemical Genetics 2008, 703-716. Springer, Springer-Verlag Berlin Heidelberg. N. Blau, M. Duran, K.M. Gibson (Eds.).
23. Herlenius E., Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Hum. Dev. 2001, 65:21-37.
24. Herlenius E., Lagercrantz H. Development of neurotransmitter systems during critical periods. Exp. Neurol. 2004, 190:S8-S21.
25. Van Der Heyden J.C., Rotteveel J.J., Wevers R.A. Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism. Eur. J. Paediatr. Neurol. 2003, 7:31-37.
26. Hilaire G., Voituron N., Menuet C., Ichiyama R.M., Subramanian H.H., Dutschmann M. The role of serotonin in respiratory function and dysfunction. Respir. Physiol. Neurobiol. 2010, 174:76-88. 10.1016/j.resp.2010.08.017.
27. Hosp J.A., Molina-Luna K., Hertler B., Atiemo C.O., Luft A.R. Dopaminergic modulation of motor maps in rat motor cortex: an in vivo study. Neuroscience 2009, 159:692-700. 10.1016/j.neuroscience.2008.12.056.
28. Hyland K. Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. Semin. Perinatol. 1999, 23:194-203.
29. Hyland K. Neurochemistry and defects of biogenic amine neurotransmitter metabolism. J Inherit. Metab. Dis. 1999, 22:353-363.
30. Hyland K. Cerebrospinal fluid analysis in the diagnosis of treatable inherited disorders of neurotransmitters metabolism. Future Neurol. 2006, 1:593-603.
31. Jan M.M.S. Misdiagnoses in children with dopa-responsive dystonia. Pediatr. Neurol. 2004, 31:298-303.
32. Kurian M.A., Gissen P., Smith M., Heales S.J.R., Clayton P.T. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011, 10:721-733. 10.1016/S1474-4422(11)70141-7.
33. Kuśmierska, K., Jansen, E.E.W., Jakobs, C., Szymańska, K., Malunowicz, E., Meilei, Rokicki, D., D., Thony B., Blau N., Tryfon,J., Pronicka, E., Sykut-Cegielska, J., 2008. Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up. doi: 10.1007/s10545-008-1009-4.
34. Longo N. Disorders of biopterin metabolism. J. Inherit. Metab. Dis. 2009, 32:333-342.
35. Marín-Valencia I., Serrano M., Ormazabal A., Pérez-Dueñas B., García-Cazorla A., Campistol J., Artuch R. Biochemical diagnosis of dopaminergic disturbances in paediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines. Clin. Biochem. 2008, 41:1306-1315.
36. Mehanna R., Jankovic J. Respiratory problems in neurologic movement disorders. Parkinsonism Relat. Disord. 2010, 10.1016/j.parkreldis.2010.07.004.
37. Molero-Luis M., Serrano M., Ormazábal A., Pérez-Dueñas B., García-Cazorla A., Pons R., Artuch R. Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev. Med. Child Neurol. 2013, 55:559-566.
38. Monti J.M., Jantos H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog. Brain Res. 2008, 172:625-646.
39. Moran M.M., Allen N.M., Treacy E.P., King M.D. "Stiff Neonate" with mitochondrial DNA depletion and secondary neurotransmitter defects. Pediatr. Neurol. 2011, 45:403-405.
40. Ng J., Zhen J., Meyer E., Erreger K., Li Y., Kakar N., Ahmad J., Thiele H., Kubisch C., Rider N.L., Morton D.H., Strauss K.A., Puffenberger E.G., D'Agnano D., Anikster Y., Carducci C., Hyland K., Rotstein M., Leuzzi V., Borck G., Reith M.E.A., Kurian M.A. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 2014, 137:1107-1119. 10.1093/brain/awu022.
41. Pacia S.V., Doyle W.K., Broderick P.A. Biogenic amines in the human neocortex in patients with neocortical and mesial temporal lobe epilepsy: identification with in situ microvoltammetry. Brain Res. 2001, 899:106-111.
42. Papousek M., Schieche M., Wurmser H. Disorders of Behavioral and Emotional Regulation in the First Years of Life. Early Risk and Intervention in the Developing Parent-Infant Relationship 2008, Zero to Three, Washington DC.
43. Pons R. The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. J. Inherit. Metab. Dis. 2009, 32:321-332.
44. R Core Team, 2013. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/
45. Richerson G.B., Buchanan G.F. The serotonin axis: Shared mechanisms in seizures, depression, and SUDEP. Epilepsia 2011, 52(Suppl. 1):S28-S38.
46. Shimizu S., Mizuguchi Y., Ohno Y. Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol. Disord. Drug Targets 2013, 12:861-869.
47. Stahl S.M., Faull K.F., Barchas J.D., Berger P.A. CSF monoamine metabolites in movement disorders and normal aging. Arch. Neurol. 1985, 42:166-169.
48. Szymańska, K., Szczałuba, K., Ługowska, A., Obersztyn, E., Radkowski, M., Nowakowska, B.A., Kuśmierska, K., Tryfon, J., Demkow U., 2014. The Analysis of Genetic Aberrations in Children with Inherited Neurometabolic and Neurodevelopmental DisordersBioMed Research International. http://dx.doi.org/10.1155/2014/424796
49. Takeuchi Y., Matsushita H., Sakai H., Kawano H., Ochi M. Developmental changes in cerebrospinal fluid concentrations of monoamine-related substances in patients with dentatorubral-pallidoluysian atrophy. J. Child Neurol. 2001, 16:79-82.
50. Temudo T., Rios M., Prior C., Carrilho I., Santos M., Maciel P., Sequeiros J., Fonseca M., Monteiro J., Cabral P., Vieira J.P., Ormazabal A., Artuch R. Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment. Brain Dev. 2009, 31:46-51.
51. Weinshenker D., Szot P. The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharamcol. Ther. 2002, 94:213-233.
52. Wong P.C.M., Morgan-Short K., Ettlinger M., Zheng J. Linking neurogenetics and individual differences in language learning: the dopamine hypothesis. Cortex 2012, 48:1091-1102.
53. Diagnostic Classification of Mental Health and Developmental Disorders in Infancy and Early Childhood 2005, ZERO TO THREE, Zero to Three, Washington, DC.